Komarom-Esztergom Varmegyei Szent Borbala Korhaz
- Address
- lock Available on a paid plan
Bacterial Infections and Mycoses
The hospital is conducting studies aimed at preventing Clostridioides difficile infection recurrence and evaluating novel antibody treatments.
- Recurrence prevention in C. difficile
- AZD5148 monoclonal antibody efficacy
- Safety of new anti‑infective agents
- Impact on hospital infection rates
These trials contribute to improved infection control at Komarom-Esztergom Varmegyei Szent Borbala Korhaz.
Digestive System Diseases
Researchers are testing innovative therapies for inflammatory bowel disease, targeting both Crohn's disease and ulcerative colitis.
- Upadacitinib maintenance in Crohn's disease
- Etrasimod induction and maintenance
- Long‑term safety of mirikizumab
- Obefazimod for refractory Crohn's disease
- AVT16 biosimilar comparison in ulcerative colitis
The site currently hosts multiple IBD trials, reflecting its expertise in gastroenterology.
Hemic and Lymphatic Diseases
The center is evaluating new approaches for blood‑related malignancies and marrow disorders.
- B‑cell lymphoma targeted therapy
- Myelodysplastic syndrome transfusion independence
- Momelotinib extended access in myelofibrosis
- Post‑PV/ET myelofibrosis treatment strategies
- Investigational agents for primary immune thrombocytopenia
These studies enhance hematologic care at the Tatabanya facility.
Immune System Diseases
Studies focus on modulating the immune response in autoimmune and hematologic conditions.
- Novel therapies for immune thrombocytopenia
- Safety monitoring of immune‑targeted agents
- Combination immunotherapy in oncology
- Cytokine inhibitor evaluation
- Immunotherapy safety in advanced NSCLC
The research supports a comprehensive immune‑focused program at Komarom-Esztergom Varmegyei Szent Borbala Korhaz.
Neoplasms
A broad portfolio of oncology trials investigates targeted and immunotherapies across solid tumors and prostate cancer.
- MET‑aberrant NSCLC therapy
- Tarlatamab versus standard care in small cell lung cancer
- DB‑1303 in HER2‑low, hormone‑receptor‑positive breast cancer
- Bemarituzumab plus chemotherapy for FGFR2b‑positive gastric cancer
- HRR‑mutated metastatic castration‑sensitive prostate cancer combination
Oncology research is a major component of the 51 trials conducted at this Hungarian site.
Nervous System Diseases
Clinical research includes disease‑modifying strategies for neurodegenerative disorders.
- Long‑term safety of a Parkinson's disease therapy
- Remibrutinib trial in secondary progressive multiple sclerosis
- CNS MET alteration targeted agents
- Biomarker studies in neuro‑immune interaction
- Quality‑of‑life assessments in neurological patients
These initiatives expand the neurological expertise of the research department.
Otorhinolaryngologic Diseases
Trials aim to reduce symptoms of chronic rhinosinusitis with nasal polyps using biologic agents.
- Benralizumab effect on nasal polyp burden
- Lebrikizumab for nasal congestion severity
- Patient‑reported outcomes in CRSwNP
- Combination with intranasal corticosteroids
- Quality‑of‑life impact assessments
The otolaryngology team at the hospital is actively advancing biologic therapies for sinus disease.
Respiratory Tract Diseases
Research targets improved management of chronic obstructive pulmonary disease and related airway conditions.
- CHF6001 add‑on therapy for COPD exacerbations
- Asthma overlap studies with CRSwNP
- Novel inhaled agents for chronic bronchitis
- Long‑term safety of bronchodilator regimens
- Lung function outcomes in treated participants
These respiratory trials support better disease control for patients in the Tatabanya region.
Other Therapeutic Areas
The facility also supports diverse investigations where disease classification is unspecified, reflecting a flexible research environment.
- Sepsis‑associated acute kidney injury study
- Biomarker discovery across multiple cancers
- Cross‑disciplinary safety monitoring programs
- Health‑economic outcomes of trial participation
- Patient‑reported outcome measure development
This breadth of work underscores the site’s commitment to advancing medical knowledge across many fields.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 5 of 9 therapeutic areas and 15 of 101 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Top 40 of 101 compounds, ranked by number of trials.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 14 by active trials.
- 1Eli Lilly & Co.5active
lock +13 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
lock +11 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 332 other sites in Hungary
Therapeutic Area Benchmark — Hungary
Select a therapeutic area to compare against other sites in Hungary.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Hungary
Market Share
Country: Hungary
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Komarom-Esztergom Varmegyei Szent Borbala Korhaz
lock Showing 1 of 58 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A Phase 2b/3 Randomized, Double-blind, Placebo-Controlled, Parallel Group, Multicenter Protocol to Evaluate the Efficacy and Safety of Icotrokinra in Participants With Moderately to Severely Active Crohn's Disease | Janssen Cilag International | Phase IV | Recruiting | Dec 2025 | — |
IMP list
lock Showing 1 of 101 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Pembrolizumab | 6 | Unknown | 2015-11-06 | 2026-06-01 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.